Drugs & Medical Devices
Get ready for the next wave of pharmaceutical litigation with HarrisMartin's Drugs & Medical Devices. This reporter will keep you one step ahead of drug and medical device litigation with in-depth investigations, guest commentaries and objective courtroom coverage on today's and tomorrow's hottest drugs and supplements.
SEARCH THE ARCHIVES
A federal judge has dismissed a multi-count complaint alleging defects in Smith & Nephew’s R3 Acetabular Hip System, saying the claims are either preempted under the Medical Device Amendments of 1976 or fail to state a claim for relief.
Mesh Plaintiffs Accuse Ethicon of ‘Severe’ Destruction of Evidence, Seek Default Judgment in Bellwethers
Plaintiffs in a consolidated federal transvaginal mesh docket have accused Ethicon Inc. and Johnson & Johnson (NYSE: J&J) of systematically destroying evidence that they say is needed to fully present their injury claims to jurors at the upcoming bellwether trials.
A Missouri federal judge has remanded an Infuse bone graft case to state court, finding the nondiverse surgeon defendant was not fraudulently joined and that the case does not arise under federal law within the meaning of 28 U.S.C. § 1331.
Strict liability, negligence and warranty claims brought against the makers of generic Reglan are federally preempted because they sound in failure to warn and therefore must be dismissed, the 6th Circuit U.S. Court of Appeals has affirmed.
A federal judge in Michigan has remanded a Rejuvenate hip lawsuit to state court after rejecting defense assertions that Michigan-based Stryker Corp. was fraudulently joined to defeat diversity jurisdiction.
A failure-to-warn claim asserted against Bristol-Meyers Squibb Co. by a plaintiff who claims Abilify causes dystonia was inadequately pled and must be dismissed, a Pennsylvania federal judge has ruled.
A North Carolina federal magistrate judge has limited the testimony of a plaintiff’s expert witness in a generic Reglan case, ruling that he may not suggest PLIVA USA Inc. had a duty to provide warnings other than those approved for the brand-name label.
A Louisiana federal judge has dismissed design defect claims brought against the makers of generic Dilantin, ruling they are federally preempted pursuant to Mutual Pharmaceutical Company Inc. v. Bartlett.
A suit brought by a woman who says Paxil caused her unborn fetus to die is barred by Pennsylvania’s two-year statute of limitations, the Pennsylvania Superior Court has affirmed, finding the plaintiff failed to show that the limitations period was tolled by fraudulent concealment.
A Pennsylvania federal judge has dismissed with prejudice an Aredia/Zometa injury case, finding the husband of the deceased plaintiff failed to timely file a suggestion of death and a motion to substitute.